Aug. 14, 2002 Sertraline was safe and effective for treating major depression in patients with recent myocardial infarction (MI) or unstable angina, according to results of a randomized, double-blind trial published in the August 14 issue of The Journal of the American Medical Association.
“More than a million individuals in the U.S. experience acute coronary syndrome (ACS) each year and approximately 20% percent of these persons will also experience major depression, which imparts a three-fold increase in the risk of morbidity and mortality,” write Alexander H. Glassman, MD, of the New York State Psychiatric Institute, and colleagues. “Even a modest reduction in risk, given the prevalence of these two conditions, would have significant public health consequences.”
This trial, conducted in 40 outpatient cardiology centers and psychiatry clinics in the U.S., Europe, Canada, and Australia, enrolled 369 patients with major depressive disorder. Average age was 57.1 years, 64% were male, 74% had a recent MI, and 26% had unstable angina. Enrollment began in April 1997, and follow-up ended in April 2001. After a two-week, single-blind placebo period, patients were randomized to 24 weeks of treatment with sertraline in flexible dosages of 50 to 200 mg per day or placebo.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!